NZ758480A - Compositions and methods for immunooncology - Google Patents

Compositions and methods for immunooncology

Info

Publication number
NZ758480A
NZ758480A NZ758480A NZ75848016A NZ758480A NZ 758480 A NZ758480 A NZ 758480A NZ 758480 A NZ758480 A NZ 758480A NZ 75848016 A NZ75848016 A NZ 75848016A NZ 758480 A NZ758480 A NZ 758480A
Authority
NZ
New Zealand
Prior art keywords
nucleic acid
molecule
grna
grna molecule
car
Prior art date
Application number
NZ758480A
Other versions
NZ758480B2 (en
Inventor
Ming-Wei Chen
Melissa Deck
Glenn Dranoff
Craig Mickanin
Reynald Lescarbeau
Celeste Richardson
Morag Stewart
Yi Yang
Original Assignee
Novartis Ag
Intellia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Intellia Therapeutics Inc filed Critical Novartis Ag
Priority to NZ782859A priority Critical patent/NZ782859B2/en
Priority to NZ782849A priority patent/NZ782849B2/en
Priority to NZ782855A priority patent/NZ782855B2/en
Priority to NZ782858A priority patent/NZ782858B2/en
Priority to NZ782857A priority patent/NZ782857B2/en
Publication of NZ758480A publication Critical patent/NZ758480A/en
Publication of NZ758480B2 publication Critical patent/NZ758480B2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to a gRNA molecule comprising a tracr and crRNA, wherein the crRNA comprises a targeting domain complementary to a target sequence of T Cell Receptor Alpha (TRAC).

Claims (17)

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:
1. A gRNA le comprising a tracr and crRNA, wherein the crRNA comprises a targeting domain that is complementary to a target sequence of T Cell Receptor Alpha (TRAC), wherein the ing domain comprises SEQ ID NO: 5528.
2. The gRNA molecule of claim 1, wherein the ing domain and the tracr are disposed on separate nucleic acid molecules.
3. The gRNA molecule of claim 1, wherein the targeting domain and the tracr are disposed on a single nucleic acid molecule, and wherein the tracr is disposed 3’ to the targeting domain.
4. The gRNA molecule of any one of claims 1 to 3, comprising: (a) one or more phosphorothioate modification(s) at the 3’ end of a c acid molecule; (b) one or more phosphorothioate modification(s) at the 5’ end of a nucleic acid molecule; (c) one or more 2’-O-methyl cation(s) at the 3’ end of a nucleic acid molecule; (d) one or more 2’-O-methyl modification(s) at the 5’ end of a nucleic acid molecule; (e) one or more 2’ yl cation at each of the 4th-to-terminal, 3rd-toterminal , and 2nd-to-terminal 3’ residues of a nucleic acid molecule; or (f) any combination thereof.
5. A composition comprising a first gRNA molecule of any one of claims 1 to 4, and a Cas9 molecule or a nucleic acid encoding the Cas9 molecule, n the gRNA molecule and the Cas9 molecule are present in a ribonuclear protein complex (RNP).
6. The composition of claim 5, wherein the Cas9 molecule comprises any one of SEQ ID NO: 6611 or SEQ ID NO: 7821 to SEQ ID NO: 7831, or a sequence having at least 95% homology thereto.
7. The composition of claim 5 or claim 6, further comprising a second gRNA molecule; a second gRNA molecule and a third gRNA molecule; or a second gRNA molecule, a third gRNA le, and a fourth gRNA molecule, wherein each gRNA molecule of the composition is complementary to a different target sequence.
8. The composition of any one of claims 5 to 7, further comprising a template nucleic acid.
9. The ition of claim 8, wherein the template c acid encodes a chimeric antigen receptor (CAR).
10. The composition of claim 9, wherein the CAR is: (a) a CD19 CAR; (b) a BCMA CAR; (c) a CD20 CAR; (d) a CD22 CAR; (e) a CD123 CAR; (f) an EGFRvIII CAR; or (g) a mesothelin CAR.
11. A nucleic acid comprising a sequence that encodes a gRNA molecule of any one of claims 1 to 4.
12. A vector comprising the nucleic acid of claim 11.
13. An o method of altering a target sequence of a cell, comprising contacting said cell with: (a) a gRNA le of any one of claims 1 to 4 and a Cas9 molecule; (b) a gRNA molecule of any one of claims 1 to 4 and nucleic acid encoding a Cas9 molecule; (c) a nucleic acid encoding a gRNA molecule of any one of claims 1 to 4 and a Cas9 (d) a nucleic acid encoding a gRNA molecule of any one of claims 1 to 4 and a nucleic acid encoding a Cas9 molecule; (e) any of a) to d), above, and a template nucleic acid; (f) any of a) to d) above, and nucleic acid comprising sequence encoding a template nucleic acid; or (g) the composition of any one of claims 5 to 10.
14. The ex-vivo method of claim 13, n the gRNA molecule or nucleic acid encoding the gRNA molecule, and the Cas9 molecule or nucleic acid encoding the Cas9 molecule, are formulated in a single composition or more than one composition.
15. An ex-vivo method of preparing cells for immunotherapy comprising modifying cells to reduce or ate expression of TRAC by ucing into said cells a gRNA molecule of any one of claims 1 to 4, and wherein the method further comprises expanding said cells.
16. The ex-vivo method of claim 15, wherein the method further comprises introducing a template c acid to the cells, wherein the template nucleic acid comprises a nucleic acid sequence encoding a chimeric antigen receptor (CAR).
17. Use of the gRNA molecule of any one of claims 1 to 4, the composition of any one of claims 5 to 10, the nucleic acid of claim 11, or the vector of claim 12 in the manufacture of a medicament for treating a disease associated with expression of a tumor antigen or providing an umor immunity in a subject. o k m g Q & 03°" .Q ®@.®§a. W E m m m g *2“ m! 69% g? gm E? w £3 E ' :3 “ 3? a ”E g...“ as: 3%,. m mum E wags...“ 5m WNW ‘3 EELS“ m g E a; N ?g? ? 3 Wa‘ g 100 C3 C3 C3 C3 C23 GD (0 '6' N {gm} aa M32951 HEW SUBSTITUTE SHEET (RULE 26) ma?a; Maze: \\\\\\\\\\\\\\\\\\\\\g m?hmw gated Mém‘sms?asamg ________ _____ _____ SUBSTITUTE SHEET (RULE 26) E 1.3 Day 3322*; 74 74 \
NZ758480A 2016-12-02 Compositions and methods for immunooncology NZ758480B2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
NZ782859A NZ782859B2 (en) 2016-12-02 Compositions and methods for immunooncology
NZ782849A NZ782849B2 (en) 2016-12-02 Compositions and methods for immunooncology
NZ782855A NZ782855B2 (en) 2016-12-02 Compositions and methods for immunooncology
NZ782858A NZ782858B2 (en) 2016-12-02 Compositions and methods for immunooncology
NZ782857A NZ782857B2 (en) 2016-12-02 Compositions and methods for immunooncology

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562263169P 2015-12-04 2015-12-04
US201662316784P 2016-04-01 2016-04-01
US201662394290P 2016-09-14 2016-09-14
NZ74388716 2016-12-02

Publications (2)

Publication Number Publication Date
NZ758480A true NZ758480A (en) 2025-07-25
NZ758480B2 NZ758480B2 (en) 2025-10-29

Family

ID=

Similar Documents

Publication Publication Date Title
PH12020551907A1 (en) Antagonizing cd73 antibody
PH12020551317A1 (en) Anti-cd73 antibodies and methods of use thereof
MX2022007575A (en) Anti-cd73 antibodies and uses thereof.
IL258215B (en) An anti-mesothelin antibody, encoding said nucleic acid, a vector consisting of said nucleic acid, a host cell consisting of said vector, a preparation method of said antibody, and a pharmaceutical antibody
PE20200839A1 (en) ANTI-CD137 ANTIBODIES
WO2018191502A3 (en) Anti-cd137 antibodies and methods of use thereof
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
IL268620B1 (en) Anti-lag3 antibodies, pharmaceutical formulations comprising them and uses thereof for treating cancer
EP4389226A3 (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
MX2021013219A (en) CELLS EXPRESSING A RECOMBINANT RECEPTOR OF A MODIFIED TGFBR2 LOCUS, RELATED POLYNUCLEOTIDES AND METHODS.
IL295858B1 (en) gRNA MOLECULES COMPRISING A TRACR AND A crRNA, COMPOSITION COMPRISING THE SAME AND THEIR USE
NZ783534A (en) Compositions and methods for the treatment of hemoglobinopathies
PE20191717A1 (en) ANTI-TRBC1 ANTIGEN UNION DOMAIN
PH12017500918A1 (en) Antibodies against cd73 and uses thereof
JP2018520654A5 (en)
PH12021552790A1 (en) Materials and methods for modulating t cell mediated immunity
WO2017040344A3 (en) Chimeric polypeptide assembly and methods of making and using the same
PL422231A1 (en) CAR immune cells for cancer treatment
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2020070678A3 (en) Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
WO2021163562A3 (en) Compositions and methods comprising splicing-derived antigens for treating cancer
MX2025012294A (en) Multispecific antibody targeting c-met
WO2020084102A3 (en) Oncolytic virotherapy and immunotherapy
MX2025000487A (en) Anti-mesothelin antibodies
NZ758480B2 (en) Compositions and methods for immunooncology

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2026 BY COMPUTER PACKAGES INC

Effective date: 20251126